MAPT and dementia: These findings, together with our current results demonstrating a beneficial effect of anti-PD-L1 in the DM-hTAU model of dementia (Figs. 3 and 4), prompted us to test whether the observed beneficial effect of targeting PD-L1 on cognitive function and disease pathology in this tau mouse model was also associated with enhanced trafficking of immune cells to the diseased brain.